

Vaccine Reference Guide Human Papillomavirus (HPV) Vaccine

Human Papillomavirus (HPV) Vaccine (Gardasil®) Quadrivalent (Types 6, 11, 16, 18) Recombinant	
<p><u>Vaccine Contents:</u> HPV 6 L1 protein, HPV 11 L1 protein, HPV 16 L1 protein, HPV 18 L1 protein Potential Allergens: polysorbate 80, yeast Other Ingredients: Amorphous aluminum hydroxyphosphate sulfate, L-histidine, sodium borate <u>Packaging:</u> The vaccine is a white, cloudy liquid. It is presented in a 0.5 mL single dose Type I glass vial. The vial is latex-free. The product does not contain a preservative or antibiotics.</p>	
<p>Store between 2 – 8° C. The vaccine should be well shaken prior to use.</p>	
RECIPIENTS	SCHEDULE
<p>Provided free to:</p> <p>(1) Healthy females born on or after January 1, 1997 are eligible to receive the HPV vaccine, routinely provided in Grade 6.</p> <p>(2) Healthy males born on or after January 1, 2002 are eligible to receive the HPV vaccine in Grade 6, as well as in the Grade 8 catch-up program in 2017-18.</p> <p>.....</p> <p>(3) For those who missed the school-based program in the eligible birth years indicated above, a 3 dose schedule is recommended unless the first dose of vaccine was administered before the age of 15.</p> <p>(4) Immunocompetent HIV-infected and/or immunocompromised females (born during or after 1997) and males (born during or after 2002) are eligible to receive 3 doses. Refer to Manitoba Health eligibility criteria for description of immunocompromising conditions.</p>	<p>2 doses*: 0.5 mL IM at 0 and 6 months (minimum interval between doses is 24 weeks).</p> <p><i>* A 3-dose schedule is recommended for individuals ≥ 15 years, unless the first dose of vaccine was administered before age 15.</i></p> <p>.....</p> <p>3 doses*: 0.5 mL IM, preferably at 0 – 2 – 6 months (minimum 1 month between first & second doses, 3 months between second & third doses, and 6 months between the first & third doses).</p> <p><i>* A 3-dose schedule is recommended for individuals ≥ 15 years, unless the first dose of vaccine was administered before age 15.</i></p>
<p>Not provided free in Manitoba but:</p> <p>(6) Recommended by the National Advisory Committee on Immunization (NACI):</p> <ul style="list-style-type: none"> • Females 9 - 26 years of age (who are not indicated above) • Males 9 - 26 years of age (who are not indicated above) <p>(7) May be administered to women and men 27 years of age and older who are at ongoing risk of exposure to HPV.</p>	

CONTRAINDICATIONS:

1. History of anaphylactic reaction to a previous dose of Gardasil® vaccine or to any component of Gardasil® vaccine.
2. Pregnancy - the data on vaccination in pregnancy are limited. Administer vaccine series after completion of pregnancy.

SPECIAL CONSIDERATIONS:

1. Individuals may be immunized even if already sexually active, as they may not yet have HPV infection and are very unlikely to have been infected with all four types of HPV found in the vaccine.
2. NACI advises that women who have had previous Pap test abnormalities, cervical cancer or genital warts would benefit from receiving HPV vaccine. Women should be advised that the vaccine does not have any therapeutic effect on pre-existing cervical disease.
3. Sexually active women who have been vaccinated with Gardasil® should continue regular Pap screening.
4. Individuals immunocompromised by disease or medication can be immunized; however, the immune response may be less than in immunocompetent individuals.

ADVERSE EVENTS:

- **Local:** pain, swelling, redness
- **Systemic:** headache, fever

SOURCE: *Gardasil® Product monograph Merck Canada March 2015 and Canadian Immunization Guide (Government of Canada online).*